Treatment of renal cell carcinoma
US11078278B2 · kind B2 · utility
1Cited by
45References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2016 |
| Grant date | Aug 3, 2021 |
| Priority date | — |
| Expiry date | Feb 16, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides methods for treating a subject afflicted with a tumor derived from a renal cell carcinoma. The methods comprise administering a first dose to a subject of an anti-PD-1 antibody or antigen-binding portion thereof and/or an anti-PD-L1 antibody or antigen-binding portion thereof, and administering a second dose to the subject, wherein the subject exhibited differential expression in one or more biomarker genes, e.g., CTLA-4, TIGIT, and/or PD-L2, following administration of the first dose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.